Subjects
This retrospective study was approved by the institutional review board (#013-0422).
We retrospectively analyzed the imaging reports of the patients suspected of having MTX-LPD who underwent PET/CT scanning at Hokkaido University Hospital during the period from June 2009 to December 2014. We searched the electronic database of all PET/CT scans performed during this time period to identify the patients suspected of having MTX-LPD, and the clinical or histological diagnosis was confirmed by review of each patient’s electronic medical records.
A total of 26 patients suspected of having MTX-LPD were identified by the review. The diagnosis of MTX-LPD was made in 22 of these patients. Regarding the other three patients, they were diagnosed with other pathologies (i.e., lung cancer, chronic lymphocytic leukemia, reactive lymph node in one patient each), and the association between MTX treatment and the remaining diagnosed plasma cytoma was unclear; these patients were therefore excluded from the analyses. We also excluded the cases of five patients who were followed up or received additional therapy at another hospital and two patients whose MTX was withdrawn before FDG PET/CT. The final study population was 15 patients with MTX-LPD (62.0 ± 10.7 years old, five men, ten women). Their characteristics are summarized in Table
1. The reasons for MTX therapy were RA (
n = 13), polyarteritis nodosa (
n = 1), and psoriatic arthritis (
n = 1). The mean duration of MTX treatment was 84.1 ± 59.6 months (range 7–234 months). Nodal regions of lymphoma were observed in 11 of the 15 patients. Extranodal regions of lymphoma were observed in eight of the patients, including the gingiva (
n = 2), skin/subcutaneous site (
n = 4), lung (
n = 4), liver (
n = 2), pericardium (
n = 1), bowel (
n = 1), bone (
n = 1), tonsil (
n = 1) and adrenal (
n = 1).
Table 1
Characteristics of the 15 patients with MTX-LPD
1 | 70s | RA | 48 | 8 | 259 | 212 | 0 | FL | - | I | 1 | non-CR |
2 | 70s | RA | 138 | 6 | 5861 | 190 | 3 | DLBCL | - | IV | 4 | non-CR |
3 | 60s | RA | 234 | 8 | 3744 | 292 | 3 | - | + | III | 4 | non-CR |
4 | 70s | RA | 103 | 6 | 310 | 241 | 1 | MALT lymphoma | N/A | II | 2 | CR |
5 | 60s | PN | 40 | 15 | 670 | 254 | 1 | DLBCL | + | IV | 4 | non-CR |
6 | 50s | PA | 83 | 10 | 3157 | 336 | 2 | - | + | IV | 3 | CR |
7 | 50s | RA | 101 | 10 | 737 | 229 | 0 | polymorphic BLPD | - | III | 1 | non-CR |
8 | 70s | RA | 50 | 8 | 864 | 209 | 1 | polymorphic BLPD | + | IV | 3 | CR |
9 | 70s | RA | 13 | 4 | 503 | 221 | 1 | DLBCL | - | IE | 1 | CR |
10 | 40s | RA | 7 | 8 | 758 | 149 | 0 | - | N/A | II | 0 | CR |
11 | 50s | RA | 48 | 6 | 340 | 176 | 1 | polymorphic BLPD | + | IIE | 0 | CR |
12 | 40s | RA | 48 | 16 | 1370 | 192 | 1 | - | - | III | 1 | CR |
13 | 60s | RA | 116 | 8 | 1136 | 242 | 1 | DLBCL | - | IV | 3 | CR |
14 | 50s | RA | 60 | 16 | 852 | 231 | 1 | MZL | + | IV | 3 | non-CR |
15 | 60s | RA | 172 | 8 | 402 | 252 | 0 | DLBCL | + | IV | 4 | CR |
Pathological data were obtained using tissue specimens obtained by biopsy or resection from 11 patients. The other four patients were diagnosed based on their clinical course. The pathologically confirmed histological types were diffuse large B-cell lymphoma (n = 5), pleomorphic B-cell lymphoproliferative disease (n = 3), follicular lymphoma (n = 1), mucosa-associated lymphoid tissue lymphoma (n = 1), and marginal zone lymphoma (n = 1). After the withdrawal of MTX, nine of the 15 patients (60.0 %) achieved a CR, and the other six patients (40.0 %) were non-CR. The mean follow-up duration was 31.7 ± 19.4 months (range 9–67 months).
PET/CT imaging
All patients underwent 18F-FDG PET/CT acquisitions using an integrated PET/CT scanner (Biograph 64 PET/CT scanner, Asahi-Siemens Medical Technologies, Tokyo). Before tracer injection, the patient fasted for at least 6 h. Following a blood glucose test to confirm blood glucose levels less than 150 mg/dL, PET images were acquired 60 min after an intravenous injection of 18F-FDG (4–5 MBq/kg). Emission scanning for 3 min per bed was carried out following the CT image acquisition for attenuation corrections.
The acquired datasets were corrected for attenuation, dead-time and scatter, and the images were reconstructed using a point spread function-based iterative algorithm (TrueX, Siemens) [
18] with two iterations per 21 subsets with 512 × 512-pixel matrix, a matrix size of 168 × 168, a voxel size of 4.1 × 4.1 × 2.0 mm, and a Gaussian filter at 4.0- mm full-width at half-maximum. The transaxial and axial field of views were 58.5 cm and 21.6 cm, respectively.
Image analyses
Each patient’s disease stage was determined by the Ann Arbor classification system for malignant lymphoma [
19]. Staging was confirmed by clinical follow-up or biopsy. We also divided the whole body into 16 nodal regions and nine extranodal anatomic regions for analysis, in accord with previous studies [
20‐
22] (Table
2).
Table 2
Nodal and extranodal regions for region-based analysis
Waldeyer ring | Upper aerodigestive tract |
Right necka | Skin/subcutaneous |
Left necka | Central nervous system and spinal canal |
Right infraclavicular | Lung |
Left infraclavicular | Myocardium |
Right axillary and pectoral | Bone and bone marrow |
Left axillary and pectoral | Liver |
Mediastinal | Bowel |
Hilar | Renal and adrenal |
Spleen | |
Paraaortic | |
Mesenteric | |
Right iliac | |
Left iliac | |
Right inguinal and femoral | |
Left inguinal and femoral | |
We compared each patient’s FDG-PET/CT findings with the results of the corresponding imaging examinations in terms of the presence of MTX-LPD disease. We classified the findings as follows. TP: true-positive (presence of MTX-LPD), TN: true-negative (absence of MTX-LPD), FP: false-positive (abnormal FDG uptake unrelated to MTX-LPD), or FN: false-negative (missed diagnosis of proved MTX-LPD) according to the reference standard. The reference standard included histopathologic findings (obtained by biopsy) or informative follow-up (clinical, laboratory, PET/CT, or other imaging findings such as endoscopy, MRI, and ultrasonography). It was impossible to obtain histopathologic proof of all of the suspected lesions in most of the clinical situations, especially in the patients with systemic disease spread. We therefore set the reference standard by using the method comparing PET/CT and MDCT findings in studies similar to ours [
23,
24].
For example, in the case of a patient entering remission, lesions that were resolved on follow-up imaging were considered TP, and lesions that remained stable or progressed were considered FP. In the case of a patient experiencing disease progression, lesions that progressed were considered TP, and lesions that resolved or remained stable on follow-up imaging were considered FP. A region was considered FN if a lesion was not seen by one modality but was identified by another modality and met the criteria for a TP result as described above. A region was considered an FN if lesions were seen but were considered non-malignant on FDG-PET/CT or MDCT and disease developed at the same site of follow-up. Regions were considered TN when the site remained disease-free at the follow-up after MTX withdrawal.
The clinical images were independently evaluated in random order by two nuclear medicine physicians (S.W. and O.M.) for 18F-FDG PET/CT and two diagnostic radiologists (Y.K. and N.M.) for MDCT. The readers were blinded to all clinical information, the results of the other imaging modalities, such as endoscopy, MRI, and ultrasonography before MTX withdrawal, and the evaluation by the other reader.
Thirty-three lymph node regions and 18 extranodal anatomic regions were out of the field of view of the anatomical CT scanning. Therefore, a final total of 207 lymph node regions and 117 extranodal anatomic regions were analyzed. Areas with focally increased 18F-FDG uptake were considered to be sites of active disease for PET/CT. For the MDCT analysis, abnormal lymph nodes were defined as having a minimum dia. >1 cm and extranodal lesion as mass lesions considered as equivocal or positive for malignancy. All regions were evaluated as positive or negative. If there was a discordant finding between the two readers, consensus was obtained by discussion. Lesions considered positive, suggestive or equivocal for MTX-LPD were considered positive for the analysis. Lesions reported as unlikely or negative for MTX-LPD were considered negative for the analysis. The number of disease sites was evaluated by each physician.
In addition, one nuclear medicine physician (S.W.) assessed the 18F-FDG PET images using semi-quantitative methods. The SUVmax from the single pixel showing the highest FDG accumulation in the lesion was calculated to obtain the information of tumor activity, as [tissue radioactivity concentration (Bq/ml)] × [body weight (g)] / [injected radioactivity (Bq)]. Two volume-based parameters, the WBMTV and the WBTLG, were also measured.
The WBMTV was calculated from the 18F-FDG PET images according to the following procedure. First, the boundaries of voxels with an SUV intensity exceeding 2.5 were produced automatically. Second, the physiological uptake including that in the brain, oral cavity, pharynx, heart, stomach, liver, intestines, kidney, ureter, bladder, skeletal muscle, and any other tissues was carefully subtracted by the nuclear medicine physician. Third, false-positive lesions, such as inflammation of joints or other benign 18F-FDG-avid lesions based on MDCT or follow-up studies including physiological examination, MDCT, ultrasonography and PET/CT scan were subtracted. Finally, the total lesion glycolysis (TLG) value was calculated for every target lesion as TLG = MTV × SUVmean, and the WBTLG was calculated as the total of TLG in the entire body.
Statistical analysis
Data are expressed as the median and range. Differences in the SUVmax, WBMTV and WBTLG between two groups were tested using Welch’s t-test for categorical variables. A Bowker test was used to compare the accuracy of 18F-FDG PET/CT scans and MDCTs in detecting malignant lesions. For each analysis, p-values <0.05 were considered significant. Statistical calculations were carried out using statistical software (JMP ver. 10, SAS, Cary, NC, USA).